No Detail Found!

Meta-analysis of new treatment strategies for metastatic colorectal cancer

Author(s)
Tariq Parvez Department of Oncology, King Fahad Hospital, Al Madina Al Munawra, Kingdom of Saudi Arabia
Abdul Rehman Saleh Mahrous Department of Gastroenterology, King Fahad Hospital, Al Madina Al Munawra, Kingdom of Saudi Arabia.
Adel Fawazi Department of Gastroenterology, King Fahad Hospital, Al Madina Al Munawra, Kingdom of Saudi Arabia
Abstract
Metastatic disease is present at diagnosis in 30% of the patients with colorectal cancer (CRC), and approximately half of early-stage patients with CRC will eventually present with metastatic disease. Until recently, few chemotherapy options were available to treat metastatic colorectal carcinoma (MCRC). Fluorouracil (5-FU) with leucovorin (LV) modulation has a marginal but positive effect on survival in those patients. The recent incorporation of irinotecan (CPT-11) and oxaliplatin for the management of advanced CRC has generated further improvement in survival. The development of oral fluoropyrimidines, mimicking continuous infusion 5-FU, is convenient to use. Recently completed or ongoing clinical trials to study novel targeting agents have initiated a new era of drug development. Anti-angiogenesis drugs, tyrosine kinase inhibitors, and epidermal growth factor blockers are among the new generation of agents.
Publication Details
Page(s) 638-642
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 14, Issue: 10, Year: 2004

Request the full text from PASTIC

0

Citations

0

Downloads

91

Views